FXR an emerging therapeutic target for the treatment of atherosclerosis

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 79-92

  Mencarelli, Andrea ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; FXR; Liver metabolism; Vascular wall and macrophages

Indexed keywords

BILE ACID; CELL RECEPTOR; CHOLESTEROL; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ANIMAL; ATHEROSCLEROSIS; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; GENETICS; HUMAN; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTEROL; GLUCOSE; HUMANS; INSULIN; LIVER; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

MURINAE; MUS; RODENTIA;

EID: 77951942185     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00997.x     Document Type: Review

References (114)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352:1685-95.
2. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009, PMID: 19346330
3. Xie W, Radominska-Pandya A, Shi Y. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA. 2001, 98:3375-80.
4. Makishima M, Lu TT, Xie W. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002, 296:1313-16.
5. Kawamata Y, Fujii R, Hosoya M. A G proteincoupled receptor responsive to bile acids. J Biol Chem. 2003, 278:9435-44.
6. Reinehr R, Häussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology. 2004, 126:249-62.
7. Zollner G, Marschall HU, Wagner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006, 3:231-51.
8. Fiorucci S, Rizzo G, Donini A. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med. 2007, 13:298-309.
9. Makishima M, Okamoto AY, Repa JJ. Identification of a nuclear receptor for bile acids. Science. 1999, 284:1362-65.
10. Parks K, Blanchard SG, Bledsoe RK. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999, 284:1365-68.
11. Wang H, Chen J, Hollister K. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999, 3:543-53.
12. Goode E, Chen J. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995, 81:687-93.
13. Huber RM, Murphy K, Miao B. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene. 2002, 290:35-43.
14. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem. 2003, 278:104-10.
15. Otte K, Kranz H, Kober I. Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003, 23:864-72.
16. Kerr TA, Saeki S, Schneider M. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell. 2002, 2:713-20.
17. Wang L, Lee YK, Bundman D. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell. 2002, 2:721-731.
18. Holt JA, Luo G, Billin AN. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-91.
19. Inagaki T, Choi M, Moschetta A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-25.
20. Song KH, Li T, Owsley E. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009, 49:297-305.
21. Stravitz RT, Rao YP, Vlahcevic ZR. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase. Am J Physiol. 1996, 271. G293-303 PMID: 8770045
22. De Fabiani E, Mitro N, Anzulovich AC. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem. 2001, 276:30708-16.
23. Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol. 2005, 288:G74-84.
24. Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. Biol Chem. 2001, 276:41690-9.
25. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005, 48:5383-403.
26. Shen H, Zhang Y, Ding H. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem. 2008, 22:1-14.
27. Renga B, Mencarelli A, Migliorati M. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J Gastroenterol. 2009, 15:2097-108.
28. Lefebvre P, Cariou B, Lien F. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009, 89:147-91.
29. Fiorucci S, Mencarelli A, Distrutti E. Targetting Farnesoid-X-receptor from medicinal chemistry to disease treatment. Curr Med Chem. 2009, PMID: 19941473
30. Sinal CJ, Tohkin M, Miyata M. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000, 102:731-44.
31. Alberti S, Schuster G, Parini P. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest. 2001, 107:565-73.
32. Crouse JR. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med. 1987, 83:243-48.
33. Bateson MC, Maclean D, Evans JR. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin Pharmacol. 1978, 5:249-54.
34. Wang DQ, Tazuma S, Cohen DE. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol. 2003, 285. G 494-502 PMID: 12748061
35. Kim I, Ahn SH, Inagaki T. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007, 48:2664-72.
36. Lambert G, Amar MJ, Guo G. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem. 2003, 278:2563-70.
37. Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res. 2002, 43. 2-12 PMID: 11792716
38. Repa JJ, Berge KE, Pomajzl C. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. Biol Chem. 2002, 277:18793-800.
39. Horton JD, Shimomura I, Brown MS. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998, 101:2331-9.
40. Niesor EJ, Flach J, Lopes-Antoni I. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001, 7:231-59.
41. Ong TP, Heidor R, de Conti A. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis. 2006, 27:1194-203.
42. Hubbert ML, Zhang Y, Lee FY. Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol Endocrinol. 2007, 21:1359-69.
43. Nakahara M, Fujii H, Maloney PR. Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J Biol Chem. 2002, 277:37229-34.
44. Langhi C, Le May C, Kourimate S. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS. 2008, 582:949-55.
45. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007, 282:20799-803.
46. Zhang DW, Lagace TA, Garuti R. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007, 282:18602-12.
47. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007, 32:71-7.
48. Abifadel M, Varret M, Rabès JP. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34:154-6.
49. Cohen JC, Boerwinkle E, TH Mosley. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med. 2006, 354:1264-72.
50. Claudel T, Sturm E, Duez H. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002, 109:961-71.
51. Mencarelli A, Renga B, Distrutti E. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 2009, 296:H272-81.
52. Zhang Y, Lee FY, Barrera G. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006, 103:1006-11.
53. Cariou B, van Harmelen K, Duran-Sandoval D. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006, 281:11039-49.
54. Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet. 1974, 2:929-31.
55. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005, 25:2020-30.
56. Claudel T, Inoue Y, Barbier O. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003, 125:544-55.
57. Fruchart-Najib J, Bauge E, Niculescu LS. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun. 2004, 319:397-404.
58. Kast HR, Nguyen CM, Sinal CJ. Farnesoid x-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol. 2001, 15:1720-28.
59. Kardassis D, Roussou A, Papakosta P. Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids. Biochem J. 2003, 372:291-304.
60. Sirvent A, Claudel T, Martin G. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 2004, 566:173-7.
61. Anisfeld AM, Kast-Woelbern HR, Meyer ME. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem. 2003, 278:20420-8.
62. Hirokane H, Nakahara M, Tachibana S. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem. 2004, 279:45685-92.
63. Watanabe M, Houten SM, Wang L. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004, 113:1408-18.
64. Hartman HB, Gardell SJ, Petucci CJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009, 50:1090-100.
65. Pineda Torra I, Claudel T, Duval C. Bile acids induce the expression of the human peroxisome proliferator- activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003, 17:259-72.
66. Staels B, Dallongeville J, Auwerx J. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998, 98. 2088-93 PMID: 9808609
67. Duran-Sandoval D, Mautino G, Martin G. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004, 53:890-8.
68. Zhang Y, Lee FY, Barrera G, Lee H. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006, 103:1006-11.
69. Ma K, Saha PK, Chan L. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006, 116:1102-9.
70. Yamagata K, Daitoku H, Shimamoto Y. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004, 279:23158-65.
71. Cariou B, van Harmelen K, Duran-Sandoval D. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006, 281:11039-49.
72. Rizzo G, Disante M, Mencarelli A. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006, 70:1164-73.
73. He F, Li J, Mu Y. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res. 2006, 98:192-9.
74. Li J, Wilson A, Kuruba R. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008, 77:169-77.
75. Qin P, Tang X, Elloso MM. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am J Physiol Heart Circ Physiol. 2006, 291:H741-7.
76. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007, 3:46-56.
77. Biddinger SB, Hernandez-Ono A, Rask-Madsen C. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008, 7:125-34.
78. Hu T, Chouinard M, Cox AL. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem. 2006, 281:39831-8.
79. Mallamaci F, Tripepi G, Maas R. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004, 15:435-41.
80. Ravani P, Tripepi G, Malberti F. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005, 16:2449-55.
81. Stählinger MC, Abbasi F, Chu JW. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc. 2002, 287:1420-6.
82. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003, 4:33-40.
83. Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?. Curr Opin Nephrol Hypertens. 2006, 15:314-20.
84. Yang G, Wu L, Jiang B. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008, 322:587-90.
85. Wang Y, Zhao X, Jin H. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2009, 29:173-9.
86. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA. 2004, 101:3668-73.
87. Li YT, Swales KE, Thomas GJ. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007, 27:2606-11.
88. Zhang Q, He F, Kuruba R. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res. 2008, 77:560-9.
89. Nakajima M, Morishita R, Zhang L. The angiotensin II type 2 receptor antagonizes the growth effects of the AT1 receptor: gain of function study using in vivo gene transfer. Proc Natl Acad Sci USA. 1995, 92:10663-7.
90. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation. 2004, 109:8-13.
91. Savoia C, Touyz RM, Volpe M. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007, 49:341-6.
92. Molavi B, Chen J, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol. 2006, 291:H687-93.
93. Kida T, Murata T, Hori M. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2009, 296:H195-201.
94. He F, Zhang Q, Kuruba R. Upregulation of decorin by FXR in vascular smooth muscle cells. Biochem Biophys Res Commun. 2008, 372:746-51.
95. McEwan PA, Scott PG, Bishop PN. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol. 2006, 155:294-305.
96. Xu G, Guimond MJ, Chakraborty C. Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod. 2002, 67:681-9.
97. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol. 2001, 280:L1327-34.
98. Kolb M, Margetts PJ, Galt T. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med. 2001, 163:770-7.
99. Fischer JW, Kinsella MG, Clowes MM. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. Circ Res. 2000, 86:676-83.
100. Nili N, Cheema AN, Giordano FJ. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am J Pathol. 2003, 163:869-78.
101. Chodouri RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med. 2005, 2:309-31.
102. Calmus Y, Guechot J, Podevin P. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology. 1992, 16:719-23.
103. Guo GL, Santamarina-Fojo S, Akiyama TE. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta. 2006, 1761:1401-9.
104. Vavassori P, Mencarelli A, Renga B. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009, 183:6251-61.
105. Yang F, Huang X, Yi T. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-7.
106. Hanniman EA, Lambert G, McCarthy TC. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res. 2005, 46:2595-604.
107. Zhang Y, Wang X, Vales C. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2006, 26:2316-21.
108. Pullinger CR, Eng C, Salen G. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002, 110:109-17.
109. Spady D, Cuthbert JA, Willard MN. Overexpression of cholesterol 7α-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. J Biol Chem. 1998, 273:126-32.
110. Miyake JH, Duong-Polk XT, Taylor JM. Transgenic expression of cholesterol-7-α-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol. 2002, 22:121-6.
111. Ratliff EP, Gutierrez A, Davis RA. Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia. J Lipid Res. 2006, 47:1513-20.
112. Sanyal S, Bavner A, Haroniti A. Involvement of rerepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci USA. 2007, 40:15665-70.
113. Wang S, Lai K, Moy FJ. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinol. 2006, 147:4025-33.
114. Xing Y, Saner-Amigh K, Nakamura Y. The farnesoid X receptor regulates transcription of 3β-hydrosyxteroid dehydrogenase type 2 in human adrenal cells. Mol Cell Endocrinol. 2009, 299:153-62.